A LinkedIn post from Saluda Medical highlights clinical durability data for its Evoke System, a spinal cord stimulation (SCS) therapy for chronic intractable pain of the trunk and/or limbs. The post cites study results indicating that 90% of patients who responded at 3 months maintained response at 3 years, referencing a 2024 publication in Reg Anesth Pain Med.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The content also notes that the featured physician, Dr. Eric Cornidez, is a paid consultant and that his reported real‑world experience aligns with outcomes seen in the EVOKE Study. The emphasis on long‑term responder durability and closed‑loop SCS technology suggests Saluda is positioning Evoke as a differentiated, data‑driven therapy in the neuromodulation market.
For investors, the focus on three‑year durability may signal an effort to strengthen clinical and economic value propositions versus conventional SCS systems, which could support pricing power and adoption if replicated broadly. Strong long‑term outcomes, if validated in wider practice, may enhance Saluda’s competitiveness in chronic pain management and potentially support future revenue growth and partnership or reimbursement discussions.